The concept behind the employment of BTK inhibition in pemphigus is that a selective BTK inhibitor has the potential to focus on multiple pathways involved in autoimmunity, like modulation of BCR-mediated B-cell pathways, inhibition of FcεR-induced cytokine release from monocytes and macrophages, mediator release, neutrophil migration and FcγR-induced mast cell degranulation. Here, BTK is linked to pemphigus.